Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1450
| Predicate | Object |
|---|---|
| rdf:type | |
| rdfs:label |
REVLIMID (Capsule)
|
| dailymed-instance:dosage |
Myelodysplastic Syndromes: The recommended starting dose of REVLIMID (lenalidomide) is 10 mg daily with water. Patients should not break, chew or open the capsules. Dosing is continued or modified based upon clinical and laboratory findings. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it would be prudent to monitor renal function.<br/>Dose Adjustments During Treatment: Patients who are dosed initially at 10 mg and who experience thrombocytopenia should have their dosage adjusted as follows: Platelet counts Patients who experience thrombocytopenia at 5 mg daily should have their dosage adjusted as follows: Patients who are dosed initially at 10 mg and experience neutropenia should have their dosage adjusted as follows: Neutrophil counts (ANC) Patients who experience neutropenia at 5 mg daily should have their dosage adjusted as follows:<br/>Multiple Myeloma: The recommended starting dose of REVLIMID (lenalidomide) is 25 mg/day with water orally administered as a single 25 mg capsule on Days 1���21 of repeated 28-day cycles. Patients should not break, chew or open the capsules. The recommended dose of dexamethasone is 40 mg/day on Days 1���4, 9���12, and 17���20 of each 28���day cycle for the first 4 cycles of therapy and then 40 mg/day orally on Days 1���4 every 28 days. Dosing is continued or modified based upon clinical and laboratory findings. The effect of substituting lesser strengths of REVLIMID(lenalidomide) to achieve a 25 mg capsule dose is unknown.<br/>Dose Adjustments During Treatment: Dose modification guidelines, as summarized below are recommended to manage Grade 3 or 4 neutropenia or thrombocytopenia or other Grade 3 or 4 toxicity judged to be related to lenalidomide. Platelet counts Neutrophil counts (ANC) Other Grade 3/4 Toxicities For other Grade 3/4 toxicities judged to be related to lenalidomide, hold treatment and restart at next lower dose level when toxicity has resolved to���Grade 2.
|
| dailymed-instance:activeIng... | |
| dailymed-instance:genericDr... | |
| dailymed-instance:activeMoi... | |
| dailymed-instance:inactiveI... | |
| dailymed-instance:genericMe... |
lenalidomide
|
| dailymed-instance:fullName |
REVLIMID (Capsule)
|
| dailymed-instance:indicatio... |
REVLIMID (lenalidomide) is indicated for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. REVLIMID (lenalidomide) in combination with dexamethasone is indicated for the treatment of multiple myeloma patients who have received at least one prior therapy.
|
| dailymed-instance:represent... | |
| dailymed-instance:routeOfAd... | |
| dailymed-instance:name |
REVLIMID
|